As an illustration of the trial framework not as prescribing guidance the general approach observed involved: A low starting dose (2 mg once weekly) for the initial 4 weeks Incremental increases (for example, to 4 mg, 8 mg, and 12 mg) at approximately 4-weekly intervals, subject to individual tolerability Maintenance doses ranging from 4 mg to 12 mg once weekly across different trial arms These figures are provided solely to describe the research context
Tkalcevi VI et al
Age is another factor to consider
KLOW best for: reactive or redness-prone skin, active rosacea or inflammatory acne, post-procedure recovery (laser, microneedling), chronic low-grade facial inflammation
Measures and Assessments The following laboratory markers were analyzed before and after treatment: Plasma reduced glutathione Plasma oxidized glutathione Whole-blood glutathione Plasma cysteine Plasma taurine Plasma sulfate (total and free) All samples were collected under fasting conditions and analyzed at CLIA-certified labs
Even though commonly used in gene function study, all these methods have limitations in application